Here, we evaluated and compared the effects of the pan-PI3K inhibitor BKM120 and the dual PI3K/mTOR inhibitor BEZ235 on mantle, follicular, and T-cell lymphomas. Here, MTOR is linked to T-cell non-Hodgkin lymphoma.